| |
n/N
|
%
|
RR
|
95% CI
|
Adjusted RR
|
95% CI
|
|---|
|
Gender
|
|
Female
|
75/258
|
29.1
|
Ref
|
Ref
|
Ref
|
Ref
|
|
Male
|
86/279
|
30.8
|
1.09
|
(0.79–1.49)
|
1.01
|
(0.74–1.41)
|
|
Age, years
|
|
< 30
|
31/138
|
22.5
|
Ref
|
Ref
|
Ref
|
Ref
|
|
30–45
|
93/282
|
32.9
|
1.56
|
(1.02–2.37)
|
1.46
|
(0.94–2.25)
|
|
≥ 45
|
37/117
|
31.6
|
1.46
|
(0.89–2.38)
|
1.43
|
(0.86–2.37)
|
|
DR-TB classification
|
|
RR-TB by Xpert MTB/RIF
|
96/237
|
40.5
|
4.36
|
(2.60–7.30)
|
4.31
|
(2.55–7.29)
|
|
RIF mono-resistant TB
|
47/109
|
43.1
|
4.76
|
(2.70–8.36)
|
4.46
|
(2.07–7.95)
|
|
MDR-TB
|
18/191
|
9.4
|
Ref
|
Ref
|
Ref
|
Ref
|
|
HIV status at initiation
|
|
HIV negative
|
14/61
|
22.1
|
0.58
|
(0.32–1.05)
|
0.75
|
(0.47–1.20)
|
|
HIV positive on ART
|
120/351
|
33.4
|
Ref
|
Ref
|
Ref
|
Ref
|
|
HIV positive not on ART
|
16/77
|
19.5
|
0.6
|
(0.36–1.02)
|
0.73
|
(0.43–1.25)
|
|
HIV status unknown
|
11/48
|
22.9
|
0.64
|
(0.33–1.21)
|
0.76
|
(0.43–1.24)
|
|
Registration year
|
|
2011
|
19/55
|
34.5
|
Ref
|
Ref
|
Ref
|
Ref
|
|
2012
|
33/108
|
30.6
|
0.88
|
(0.50–1.56)
|
0.88
|
(0.49–1.56)
|
|
2013
|
49/166
|
29.5
|
0.81
|
(0.47–1.37)
|
0.74
|
(0.43–1.28)
|
|
2014
|
60/211
|
28.4
|
0.84
|
(0.50–1.41)
|
0.83
|
(0.49–1.41)
|
|
Time to treatment initiation
|
|
Without delay
|
70/186
|
37.6
|
Ref
|
Ref
|
Ref
|
Ref
|
|
Delayed (deferred)
|
85/332
|
25.6
|
0.97
|
(0.71–1.33)
|
0.94
|
(0.66–1.33)
|
- RR Relative Risk, CI Confidence interval, RR-TB Rifampicin resistant TB, MTB Mycobacterium tuberculosis, MDR-TB Multi-drug resistant tuberculosis, XDR-TB Extensively drug-resistant tuberculosis; DR-TB drug resistant TB, ART antiretroviral therapy, RIF rifampicin p < 0.05 bold
